FMP

FMP

Enter

TNYA - Tenaya Therapeutics,...

Financial Summary of Tenaya Therapeutics, Inc.(TNYA), Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for

photo-url-https://financialmodelingprep.com/image-stock/TNYA.png

Tenaya Therapeutics, Inc.

TNYA

NASDAQ

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

4.32 USD

0.03 (0.694%)

About

ceo

Mr. Faraz Ali M.B.A.

sector

Healthcare

industry

Biotechnology

website

https://www.tenayatherapeutics.com

exchange

NASDAQ

Description

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that...

CIK

0001858848

ISIN

US87990A1060

CUSIP

87990A106

Address

171 Oyster Point Boulevard

Phone

650 825 6900

Country

US

Employee

140

IPO Date

Jul 30, 2021

Summary

CIK

0001858848

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

87990A106

ISIN

US87990A1060

Country

US

Price

4.32

Beta

2.61

Volume Avg.

559.41k

Market Cap

339.19M

Shares

-

52-Week

1.66-8.091

DCF

0.45

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-2.57

P/B

-

Website

https://www.tenayatherapeutics.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest TNYA News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep